Calamos Advisors’s ProKidney PROK Stock Holding History

Calamos Advisors’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300,000	Closed	-$2.98M	–	1329
2022 Q2	$2.98M	Hold	300,000	–	–	0.01%	841
2022 Q1	$2.96M	Hold	300,000	–	–	0.01%	843
2021 Q4	$2.97M	Hold	300,000	–	–	0.01%	830
2021 Q3	$2.94M	Buy	300,000 +100,000	+50%	+$985K	0.01%	724
2021 Q2	$2.02M	Buy	+200,000	New	+$2.02M	0.01%	725

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Calamos Advisors's PROK Position: Q3 2022 in Review

Calamos Advisors sold out of ProKidney (PROK) in Q3 2022, closing a stake of 300,000 shares — an estimated $2.98M sold.

Calamos Advisors first reported a position in PROK in Q2 2021 and held it in 5 quarters. The position peaked at $2.98M in Q2 2022. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

Calamos Advisors reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
Calamos Advisors sold 300,000 ProKidney shares in Q3 2022, an estimated $2.98M.
Calamos Advisors first reported a position in ProKidney in Q2 2021 and held it in 5 quarters.
Calamos Advisors's ProKidney position peaked at $2.98M in Q2 2022.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Calamos Advisors's 13F filing for Q3 2022, filed 24 Oct 2022.